Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children

References

• Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. 2007. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther. 320(1):331–343.
   PubMed Web of Science ®Google Scholar
• Budi T, Toth K, Nagy A, Szever Z, Kiss A, Temesvari M, Hafra E, Garami M, Tapodi A, Monostory K. 2015. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia. 56(6):849–855.
   PubMed Web of Science ®Google Scholar
• Chen J, Su QB, Tao YQ, Qin JM, Zhou Y, Zhou S, Li HL, Chen ZJ, Zhou YF, Zhou LM, et al. 2018. ABCC2 rs2273697 is associated with valproic acid concentrations in patients with epilepsy on valproic acid monotherapy. Pharmazie. 73(5):279–282.
   PubMed Web of Science ®Google Scholar
• Chu XM, Zhang LF, Wang GJ, Zhang SN, Zhou JH, Hao HP. 2012. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol. 68(10):1395–1401.
   PubMed Web of Science ®Google Scholar
• Ethell BT, Anderson GD, Burchell B. 2003. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 65(9):1441–1449.
   PubMed Web of Science ®Google Scholar
• Feng W, Mei S, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F. 2016. Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China. Ther Drug Monit. 38(6):738–743.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. 2013. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 23(4):236–241.
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu C, He X, Qiu F, Zhao L. 2012. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet. 27(5):536–542.
   PubMed Web of Science ®Google Scholar
• Hung CC, Ho JL, Chang WL, Tai JJ, Hsieh TJ, Hsieh YW, Liou HH. 2011. Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics. 12(8):1107–1117.
   PubMed Web of Science ®Google Scholar
• Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, et al. 2014. Influence of uridine diphosphate glucuronosyltransferase 2B7-161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit. 36(3):406–409.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hansen AJ, Mackenzie PI. 2000. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol. 57(5):940–947.
   PubMed Web of Science ®Google Scholar
• Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, Muller M. 2009. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol. 65(12):1187–1193.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. 2006. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 94(2):261–271.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim JE, Choi HC, Song HK, Kang TC. 2015. Cellular and regional specific changes in multidrug efflux transporter expression during recovery of vasogenic edema in the rat hippocampus and piriform cortex. BMB Rep. 48(6):348–353.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH. 2005. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 313(3):1340–1346.
   PubMed Web of Science ®Google Scholar
• Liu M, Mao J, Xu H, Wang J, Zhao P, Xu Q, Du Z. 2020. Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children. Epilepsy Res. 168:106485.
   PubMed Web of Science ®Google Scholar
• Löscher W, Klotz U, Zimprich F, Schmidt D. 2009. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 50(1):1–23.
   PubMed Web of Science ®Google Scholar
• Marahatta A, Bhandary B, Jeong SK, Kim HR, Chae HJ. 2014. Soybean greatly reduces valproic acid plasma concentrations: a food–drug interaction study. Sci Rep. 4:4362.
   PubMed Web of Science ®Google Scholar
• Mei S, Feng W, Zhu L, Li X, Yu Y, Yang W, Gao B, Wu X, Fang F, Zhao Z. 2018. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol. 74(8):1029–1036.
   PubMed Web of Science ®Google Scholar
• Mei S, Feng W, Zhu L, Yu Y, Yang W, Gao B, Wu X, Zhao Z, Fang F. 2017. Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy. Seizure. 51:22–26.
   PubMed Web of Science ®Google Scholar
• Monostory K, Nagy A, Toth K, Budi T, Kiss A, Deri M, Csukly G. 2019. Relevance of CYP2C9 function in valproate therapy. Curr Neuropharmacol. 17(1):99–106.
   PubMed Web of Science ®Google Scholar
• Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C. 2019. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 17(10):926–946.
   PubMed Web of Science ®Google Scholar
• Sanchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Armijo JA. 2010. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 19(2):93–101.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshe SL, et al. 2017. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58(4):512–521.
   PubMed Web of Science ®Google Scholar
• Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, Wanders RJ, Tavares de Almeida I. 2008. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 31(2):205–216.
   PubMed Web of Science ®Google Scholar
• Sun YX, Zhuo WY, Lin H, Peng ZK, Wang HM, Huang HW, Luo YH, Tang FQ. 2015. The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. Epilepsy Res. 114:78–80.
   PubMed Web of Science ®Google Scholar
• Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. 2010. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg. 112(4):320–323.
   PubMed Web of Science ®Google Scholar
• Vijay N, Morris ME. 2014. Role of monocarboxylate transporters in drug delivery to the brain. Curr Pharm Des. 20(10):1487–1498.
   PubMed Web of Science ®Google Scholar
• Wang P, Lin XQ, Cai WK, Xu GL, Zhou MD, Yang M, He GH. 2018. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 74(4):433–442.
   PubMed Web of Science ®Google Scholar
• Wen ZP, Fan SS, Du C, Yin T, Zhou BT, Peng ZF, Xie YY, Zhang W, Chen Y, Tang J, et al. 2016. Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients. Pharmacogenomics. 17(11):1219–1225.
   PubMed Web of Science ®Google Scholar
• Xu ZY, Guo HL, Li L, Zhang M, Jing X, Xu ZJ, Qiu JC, Lu XP, Ding XS, Chen F, et al. 2020. Genetic and non-genetic factors contributing to the significant variation in the plasma trough concentration-to-dose ratio of valproic acid in children with epilepsy. Front Pediatr. 8:599044.
   PubMed Web of Science ®Google Scholar
• Zhao M, Chen Y, Wang M, Li G, Zhao L. 2020. Impact of age and genotype on serum concentrations of valproic acid and its hepatotoxic metabolites in Chinese pediatric patients with epilepsy. Ther Drug Monit. 42(5):760–765.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L. 2017. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity. Basic Clin Physiol Pharmacol. 121(2):138–143.
   Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Huang M. 2010. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 278(2):165–188.
   PubMed Web of Science ®Google Scholar
• Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. 2017. The pharmacogenomics of valproic acid. J Hum Genet. 62(12):1009–1014.
   PubMed Web of Science ®Google Scholar